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Abstract 
 
Aims  
Biofilms are ubiquitous and when mature have a complex structure of microcolonies in an extracellular 
polysaccharide and extracellular DNA matrix. Indwelling medical devices harbour biofilms which have been 
shown to cause infections and act as reservoirs for pathogens. Urinary catheters are often in place for 
considerable periods of time and are susceptible to both encrustation and biofilm formation. Strategies for 
minimising biofilm occurrence underpin an active research area in biomedicine. Manuka honey has, inter 
alia, well-established antibacterial properties. This study aims to assess the influence of honey on early 
biofilm formation in an established in vitro model. 
 
Methods  
An established model of early biofilm formation using static bacterial cultures in vinyl 96-well plates was 
used to grow Escherichia coli, strain ATC 25922 and Proteus mirabilis, strain 7002. Planktonic cells were 
removed and the residual biofilm was stained with crystal violet, which were subsequently eluted and 
quantified spectrophotometrically. Manuka honey (Unique Manuka Factor 15+) was added either with the 
bacteria or up to 72 hours after. 
 
Results  
Biofilms in this model was developed over 3 days, after which growth stalled. Mixed (1:1) cultures of E. coli 
and P. mirabilis grew slower than monocultures. In mixed cultures, honey gave a dose-dependent reduction 
in biofilm formation (between 3.3 and 16.7%w/v). At 72 hours, all concentrations inhibited maximally 
(<0.001). Application of honey to cultures after 24 and 48 hours also reduced the adherent bacterial 
biomass (p<0.05–p<0.01). 
 
Conclusion  
Manuka honey at dilutions as low as 3.3% w/v in some protocols and at 10% or above in all protocols tested 
significantly inhibits bacterial attachment to a vinyl substrate and reduces further early biofilm 
development. No augmentation of growth over untreated controls was observed in any experiment. 
 
  
Introduction 
 
Biofilms are ubiquitous.1 Indwelling medical devices as well as epithelial layers exposed to the environment 
engender and harbour biofilms and, in the case of devices, they have been shown to cause infections and 
act as environmental reservoirs for pathogens.2 Within a mature biofilm, bacteria are enclosed in a largely 
self-produced extracellular matrix, accounting for about 90% of the biomass.3 The matrix is made up of 
extracellular polymeric substances that, along with pili, flagella, carbohydrate-binding proteins, 
extracellular DNA and other adhesive fibres, act as a stabilising scaffold for the three-dimensional biofilm 
structure.4 Enzymes secreted adaptively by the bacteria customise biofilm architecture to the current 
environment. The result is a highly robust structure with high tensile strength that keeps bacteria in close 
proximity, allowing cell-to-cell interactions and DNA exchange, at the same time protecting the biomass 
from damaging agents.3 The maturation processes in biofilms bestows survival advantages, 5 achieved in 
part by quorum sensing6 through gene transfer, biofilm attachment and the production of virulence factors. 
The result is bacterial microcolonies exhibiting their own cyclical existence.7 
 
Indwelling urinary catheters are commonly used in medical and nursing care. Long-term catheterisation is 
associated with frequent complications, many arguably linked to inflammation and/or infection, 
encrustation and biofilm formation.8 Escherichia coli is the cause of 80%–85% of urinary tract infections.9 
Strategies for minimising their occurrence and impact underpin a currently active research area in 
biomedicine.10 
 
Honey has been used as a remedy for centuries11 but the active ingredients including glucose oxidase 
catalase and a range of polyphenols are more recently described.12 Potentially therapeutic properties 
include antibacterial and anti-inflammatory effects12 as well as modulation of angiogenesis13 and inhibition 
of induced histamine release by mast cells.14 We acknowledge that despite ample evidence of potential 
therapeutic properties, validation of topical honey applications in medicine have not been robust, as 
evidenced in three Cochrane reviews.15–17 However, in these reviews, honey does not fare worse than 
classical and well-accepted compounds such as povidone iodine and silver or peroxide-based products. In 
fact, no drug or dressing receives ringing endorsement, suggesting that the field is under-investigated or 
difficult to address. Resistance is an issue in antimicrobial therapies; studies generally assert the inability of 
bacteria to develop resistance to honey.18 This study addresses in a reproducible model system, 
fundamentally described by Merritt et al,19 the hypothesis that relatively dilute and therefore acceptably 
non-viscous dilutions of honey might have a role as a flushing agent to minimise the initial establishment 
and early development of biofilms on implanted devices such as urinary catheters. Maturation is another 
issue, not well addressed by static culture; models incorporating some sort of flow, through or across the 
affected surface, are required for progression to a complex structure.19 Prevention, however, is determined 
by inhibition of attachment and early biofilm development. 
Materials and Methods 
 
Bacteria 
Two micro-organisms from genera commonly associated with catheter-associated urinary tract infections 
were used in this study. E. coli, strain ATC 25922 and Proteus mirabilis, strain 7002 were available in-house 
on agar slopes and grown on in Luria-Bertani (LB) broth. The inoculated broth was incubated for 24 hours 
without shaking. 0.1% and 1.0% concentrations of E. coli and P. mirabilis were prepared in LB broth 
vortexed and 100 mL of the bacterial suspension was pipetted into each well of the 96-well plate. Initial 
experiments establishing the method were performed with monocultures and 1:1 v:v mixed cultures, all 
adjusted to a McFarlane 1% standard. 
 
Honey 
Manuka honey Unique Manuka Factor 15+ from Comvita (UK) was purchased from a local health food shop. 
A 50%w/v stock dilution was prepared in distilled water. 
 
Bacterial growth assay 
Round-bottomed 96-well polyurethane plates (Fisher Scientific, UK) were used to assess bacterial biofilm 
formation from a final 150 mL culture volume. At the termination of the experiment, supernatant medium 
containing planktonic bacteria was gently aspirated to clear flat-bottomed 96-well plates for measurement 
of planktonic bacteria using absorbance at 620 nm in a plate reader. Each well of the experimental plates 
was rinsed three times with 200 mL of distilled water without disturbing the adherent biofilm. The plate 
was air-dried for 5 min. Crystal violet (125 mL of 0.1%, 15 min, ambient temperature) was used to stain 
bacteria. The crystal violet was removed and each well was rinsed three times with 200 mL of distilled 
water and left to air dry. About 200 mL of 95% ethanol per well was subsequently added and the plates 
were incubated at room temperature for 15 min. The contents of each well were mixed and 125 mL of the 
crystal violet/ethanol solution was transferred to clear flat-bottomed 96-well plate. The extent of biofilm 
was determined by measuring absorbance at 593 nm. 
 
To assess the contribution of each species to the biofilms in a temporally separate series of experiments, 
wells were washed free of non-adherent organisms and adherent bacteria were wiped off and plated and 
incubated on MacConkey agar with neutral red as a discriminant colour indicator for lactosefermenting 
organisms. 
 
Experimental protocols 
Preliminary experiments demonstrated that bacteria, either as monocultures or mixed, adhered to the 
plate walls and that these biofilms developed over 3 days, after which absorbance from eluted stain 
decreased. A maximum of 3 days was, therefore, imposed on further experiments. All cultures were 
incubated aerobically at 37°C. 
 
 
 
Figure 2 Bar graph showing the effect of honey on biofilm formation over 72 hours. Dilutions of honey (50 
mL) were added directly to wells containing bacterial culture. Cultures were washed to remove planktonic 
cells and then dried. Plates were then stained with crystal violet, washed and the stain eluted with 90% 
ethanol. Plots include reagent blank (no bacteria) and a positive control with untreated bacteria. Optical 
densities were read at 593 nm. Columns represent means and SDs. The three plots represent 1, 2 and 3 
days incubation. Honey dilutions are expressed as final concentration. One-way analysis of variance yielded 
p<0.001; post-hoc analysis (GraphPad Prism) of individual results against untreated control are recorded as 
significant (α=0.05) under asterisk. 
 
 
 
Figure 3 Bar graph showing the effect of honey dilutions applied to 24-hour adherent biofilm. Plates were 
incubated for 24 hours to establish a biofilm. Honey dilutions (50 mL) per well were applied in and 
incubation was for 4 and 24 hours. Planktonic cells were removed and plates were dried. Reagent blank and 
untreated positive control are included. Optical densities read after staining and elution at 593 nm for 
crystal violet. Columns represent means and SDs. One-way analysis of variance yielded p<0.001; post-hoc 
analysis (GraphPad Prism) of individual results against untreated control are recorded as significant 
(α=0.05) under asterisk. 
 
Treatment with honey present throughout 
Five concentrations of honey (10%, 20%, 30%, 40%, 50%) were added in 50 mL of medium to two columns 
of each plate. This gave final concentrations, as reported in the Results section, of 16.7%, 13.3%, 10.0%, 
6.6% and 3.3%w/v. For controls, the first column had 50 mL of plain medium added and in the second row, 
50 mL of ‘half strength artificial honey’ (45% glucose, 48% fructose, 1% sucrose w/v final) was added. Plates 
were sealed and incubated for 24, 48 and 72 hours to assess the effect of honey on bacterial biofilm 
formation. 
 
Addition of honey after initial biofilm establishment 
Plates were seeded with bacteria as described above. After 24 hours of biofilm formation, the medium 
(containing planktonic bacteria) was discarded, 100 mL of fresh LB broth was added to each well and 
treatment with honey was initiated as described above. The treated plates were incubated for 4 or 
24 hours with honey before being prepared for staining. 
 
Statistical analysis 
Data were included in a database and analysed by GraphPad Prism (GraphPad Software, Inc., USA). Results 
are normally distributed and expressed as means±SEM. Differences between two or more groups were 
assessed by one-way analysis of variance, with pairings of each honey concentration versus controls 
assessed by the Quickcalcs post-hoc calculator. Setting α=0.05, pairs are reported as significant or not. 
 
  
Results 
 
Preliminary experiments established that, under the conditions employed, early biofilm formation assessed 
by bacterial content was optimal for study after 3 days at 37°C. Further incubation yielded no further 
growth; indeed, a tendency to reduce optical density readings was observed. 
 
Figure 1 shows honey at all five concentrations used reducing the optical density readings obtained in the 
culture supernatants (planktonic cells) after incubation by a minimum of 35% (day 2, 3.3% honey), the 
greatest reduction being 77% (day 3, 16.7%honey). Days 2 and 3 results exhibited dose-dependency across 
the range of dilutions tested. 
 
Adherent biofilm crystal violet stain was also reduced by continuous exposure to honey (figure 2), but in 
this situation dose-dependency was observed at 24 and 48 hours, giving reductions in optical density 
between 15% and 70%. At 72 hours, all the honey concentrations employed gave approximately 70% 
suppression of optical density. 
 
Application of honey dilutions to 24-hour-old established cultures for both 4 and 24 hours illustrates a 
pronounced dose response to honey for both exposure times (figure 3). However, the lowest (3.3%) honey 
concentration applied over 4 hours gave the only groups of treated wells in the study where the mean 
optical density was higher numerically (by 3% and 1.5% for the two lowest honey concentrations) than the 
untreated control. These two columns were rated ‘not significant’ on post-hoc testing. The maximum 
effects, at 16.7% honey, were 38% and 46% for 4-hour and 24-hour exposures, respectively. 
 
Differential colony-counting was performed as separate experiments, by different operatives, using 
different stock bacterial cultures and using a stored (18-month) batch of honey. The results gave responses 
to the E. coli in line with the crystal violet measurements, but the P. mirabilis was resistant to honey, at 
least to the level of the upper colony-counting limit (table 1). 
 
Discussion 
Indwelling urinary catheters are commonly used in medical and nursing care, for the management of 
bladder drainage. Approximately, 100 million catheters are sold annually worldwide20 and 15%–25% of 
patients in acute settings may be catheterised. 21 Chronic problems with urinary control affect up to 
20% of the general population, rising to 25% or more in those over the age of 75.22 
 
  
Table 1 Colony formation after 24-hour biofilm formation and subsequent contact with honey for 24 hours 
 
Honey 
concentrations   Planktonic bacteria   Biofilm bacteria   
(%)   Escherichia  Proteus  Escherichia   Proteus 
coli   mirabilis  coli    mirabilis 
(CFU)   (CFU)   (CFU)    (CFU) 
 
3.33    >1000   >1000   >1000    >1000 
6.67    >1000   >1000   >1000    >1000 
10    >1000   >1000   800    >1000 
13.33    170   >1000   180    >1000 
16.67    0   >1000   0    >1000 
CFU, colony-forming unit 
 
 
It was to be expected that Manuka honey would prove bacteriostatic, 23 as illustrated by the results on 
planktonic bacteria. There is a suggestion in the results that the active constituent(s) may be consumed or 
degraded over time, as dose-responsiveness increases with length of incubation. 
 
Adherence of bacteria, representing early biofilm formation, was strongly inhibited by honey. The shorter 
incubations showed a strong dose response, but inhibition was maximal at the lowest concentration tested, 
3.3% honey, after 72 hours at 37°C. This is not intuitively consistent with the effects noted for planktonic 
bacteria but may represent a lasting effect of early damage. Further growth of biofilms established for 24 
hours was inhibited by exposure to honey for both 4 and 24 hours, although this was a weaker inhibition 
and the dose-responsiveness was rather less smooth. Honey inhibited 48-hour-old biofilms with a steeper 
and more even dose-dependency, with the caveat that 4-hour treatment with 3.3% and 6.6% honey was 
ineffective. This pattern of results could be taken to indicate that honey sticks more effectively with 
establishment of the biofilm. 
 
It is important to note that these results relate to bacterial adhesion and early biofilm formation. 
Moreover, this biofilmmodel is, as used here, self-limiting and not capable of developing a complex matrix. 
According to reports from Merritt et al,19 these require an element of flow, through or over the substrate. 
However, the model used demonstrates a capability of honey to inhibit the formation and early 
development of biofilms on solid plastic surfaces at concentrations that are not unduly viscous. In clinical 
applications, honey instillation would also confer benefit from its independent anti-inflammatory 
properties.  
 
Studies in our laboratories on inhibition of histamine release from mast cells indicate that such activities 
can occur at relatively high dilutions of honey.24 25 Another outcome from these studies that requires 
further enquiry is that honey from different floral sources has varying activity in assays for different 
bioactivities that do not align. Antibacterial activity is generally found to be highest in dark honey such as 
Manuka, whereas the suppression of mast cell activation was maximal with the relatively light-coloured 
eucalyptus honey.24 25 Such differential activity presents a problem and also opportunities for commercial 
exploitation, in terms of processing, standardisation and blending. 
 
The apparent resistance of P. mirabilis in the colony-forming assay was surprising, as other studies have 
demonstrated antibacterial activity of Manuka honey against this species.26 27 It arguably highlights the 
variability of raw honey, even from the same floral source, with storage time and conditions as likely 
factors. An alternative explanation for the lack of dose-responsiveness is that the counting system was too 
sensitive to detect any changes that may have occurred. Further studies in this area are ongoing. 
 
In conclusion, our study demonstrates that diluted honey is potentially a useful agent for reducing biofilm 
formation on indwelling plastic devices such as urinary catheters, probably by using as a periodic flushing 
agent. This application would require the following further preclinical developments: further 
standardisation of medical-grade honey (or derivatives), storage requirements and assessments of honey 
from other floral sources. Honey would also need to be subjected to in vivo tolerability trials, probably in 
rodents at dilutions that demonstrate efficacy in vitro, yet are not too viscous for instillation. 
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